| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,422 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
500,000 |
525,000 |
525,000 |
525,000 |
| Total Buy Value |
$324,050 |
$343,050 |
$343,050 |
$343,050 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Corvese Brian |
Director |
– • – |
2020-06-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,118 |
69,614 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-06-19 |
4 |
A |
$3.83 |
$14,780 |
D/D |
3,859 |
305,763 |
|
- |
|
| Incyte Corp |
10% Owner |
– – • |
2020-06-17 |
4 |
S |
$3.66 |
$518,831 |
D/D |
(141,920) |
16,972,968 |
|
-3% |
|
| Incyte Corp |
10% Owner |
– – • |
2020-06-16 |
4 |
S |
$3.66 |
$264,007 |
D/D |
(72,080) |
17,114,888 |
|
-8% |
|
| Incyte Corp |
10% Owner |
– – • |
2020-06-15 |
4 |
S |
$3.57 |
$1,372,160 |
D/D |
(384,025) |
17,186,968 |
|
-1% |
|
| Incyte Corp |
10% Owner |
– – • |
2020-06-12 |
4 |
S |
$3.58 |
$32,556 |
D/D |
(9,100) |
17,570,993 |
|
-13% |
|
| Incyte Corp |
10% Owner |
– – • |
2020-06-11 |
4 |
S |
$3.77 |
$692,786 |
D/D |
(183,875) |
17,580,093 |
|
-13% |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-06-05 |
4 |
A |
$3.85 |
$14,776 |
D/D |
3,838 |
301,904 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-05-22 |
4 |
A |
$2.50 |
$14,778 |
D/D |
5,911 |
298,066 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-05-14 |
4 |
D |
$2.29 |
$1,738,110 |
D/D |
(759,000) |
292,155 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-05-12 |
4 |
A |
$2.56 |
$407,040 |
D/D |
159,000 |
1,051,155 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-05-08 |
4 |
A |
$2.53 |
$14,780 |
D/D |
5,842 |
892,155 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-04-24 |
4 |
A |
$2.79 |
$14,776 |
D/D |
5,296 |
1,112,282 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-04-10 |
4 |
A |
$2.50 |
$14,778 |
D/D |
5,911 |
1,106,986 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2019-12-19 |
4/A |
D |
$3.77 |
$736,500 |
D/D |
(195,358) |
1,101,075 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2019-12-19 |
4 |
D |
$3.77 |
$736,500 |
D/D |
(195,358) |
1,035,075 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2019-12-17 |
4/A |
D |
$3.88 |
$256,080 |
D/D |
(66,000) |
1,296,433 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2019-12-17 |
4/A |
A |
$3.88 |
$256,080 |
D/D |
66,000 |
1,362,433 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2019-12-17 |
4 |
D |
$3.88 |
$256,080 |
D/D |
(66,000) |
1,230,433 |
|
- |
|
| Jeynes-Ellis Allison M |
Director |
– • – |
2018-11-07 |
4 |
A |
$0.00 |
$0 |
D/D |
28,985 |
28,985 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2018-09-27 |
4 |
D |
$2.16 |
$486,000 |
D/D |
(225,000) |
1,296,433 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2018-09-27 |
4 |
A |
$2.16 |
$648,000 |
D/D |
300,000 |
1,521,433 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2018-04-06 |
4 |
D |
$4.82 |
$679,495 |
D/D |
(140,974) |
1,221,433 |
|
- |
|
| Wiinberg Ulf |
Director |
– • – |
2018-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,915 |
45,915 |
|
- |
|
| Corvese Brian |
Director |
– • – |
2018-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,220 |
21,220 |
|
- |
|
186 Records found
|
|
Page 4 of 8 |
|
|
